Adoptive immunotherapy with lymphokine activated killer (LAK) cells and interleukin-2 (IL-2) has been shown effective in the treatment of established metastatic pulmonary, hepatic, and intraperitoneal (i.p.) tumour in the mouse Lafreniere & Rosenberg, 1985; Ottow et al., 1987a) . The results of immunotherapy with IL-2 and LAK in patients with advanced cancer are encouraging and underline the potential of this new approach to the treatment of cancer (Rosenberg et al., 1987; West et al., 1987) . LAK cells are lymphoid cells that have acquired the capacity to lyse fresh tumour cells in 4 hour 51Chromium release assays (Grimm et al., 1982) . This can be achieved in vitro by a three day incubation in IL-2 and in vivo by administration of high doses of IL-2 (Ettinghausen et al., 1985) . We have recently shown that the generation of LAK cell activity in the peritoneal exudate by the administration of IL-2 is particularly effective (Ottow et al., 1987b; Eggermont et al., 1988) . Unfortunately the toxicity of high doses of IL-2 is a major obstacle to obtain cures with interleukin-2. This has brought us to explore various treatment strategies that will augment antitumour effects of (Eggermont et al., 1987a ). An attractive feature of adoptive immunotherapy with IL-2 and LAK cells is its efficacy in the immunocompromised host . Combination therapy with cytostatic agents should therefore be feasible. Here we report on the results of our investigations concerning the efficacy of combination treatment schedules using cyclophosphamide (CY), old. They were maintained on laboratory chow and acidified water ad libitum in a pathogen-free environment.
Tumour
The MCA-105 sarcoma used in these experiments was induced in our laboratory by the i.m. injection of 0.1 ml of 1% 3-methylcholanthrene (MCA) in sesame oil as described previously (Parker & Rosenberg, 1977) . A large number of vials from the first passage generation were cryopreserved. After thawing, the tumour was passaged subcutaneously and its use was restricted to the first 6 passage generations. Single cell suspensions of the tumour were prepared as described previously . Briefly, fresh tumours were excised, minced with scissors and stirred in a triple enzyme solution of deoxyribonuclease, hyaluronidase and collagenase (Sigma Chemical Co., St Louis, MO) for 3 h at room temperature, filtered through 100 gauge nylon mesh (Nitex, Lawshe Industrial Co., Bethesda, MD), washed three times in Hanks balanced salt solution (HBSS; Biofluids, Rockville, MD) without calcium (Ca2+) and magnesium (Mg2+) and resuspended at the appropriate cell concentration for injection in HBSS. In all experiments described here single cell suspensions of sarcoma MCA-105 were used. MCA-105 is a weakly immunogenic sarcoma (Papa et al., 1986) .
Interleukin-2 Human recombinant interleukin-2 was kindly supplied by the Cetus Corporation (Emeryville, CA) and had a specific activity of 3-4 x 106 units of IL-2 mg-I protein . IL-2 activity was measured by a standard bioassay as described previously (Donahue & Rosenberg, 1983 Generation of LAK cells LAK cells were generated as described previously . Briefly: BL/6 spleens were harvested aseptically and mashed in HBSS with the hub of a syringe and passed through a 100 gauge nylon mesh (Nitex) (Holland & Wolfe, 1973) . If this test showed a two sided P value .0.05, pairwise comparisons of differences in tumour load were examined with the Wilcoxon rank sum test with a correction for ties (Gehan, 1965 The results are summarized in Tables II and III. In Table II (Figure 1) . Two mice were long term survivors. After 100 days they were sacrificed and were found to have no visible tumour i.p. upon examination.
Combination treatment with CY, IL-2 and LAK cells prolongs survival most effectively after high dose tumour inoculation BL/6 mice, inoculated with 3 x 105 MCA-105 cells i.p. on day 0, were treated with CY (50mg kg -I on day 3 and 8), and/or IL-2 (25,000 units, i.p., b.i.d., from day 3 through 7) and LAK cells (1 x 108 cells on day 3). IL-2 alone did not prolong survival. The results of this experiment are depicted in Figure 2 . Treatment with CY alone, or IL-2 plus LAK cells prolonged survival modestly. A distinct prolongation of survival was seen when CY and IL-2 were combined, even though with this high initial tumour load to permanent survivors were seen. Twenty-five percent of the group of mice that received CY, IL-2 and LAK cells were longtime (NS) survivors (no i.p. tumour when autopsy was performed on day 100). Combination treatment with all three components was clearly much more effective than any other treatment schedule.
Discussion
We have shown that chemoimmunotherapy with cyclophosphamide and IL-2 or IL-2 plus LAK cells has superior antitumour activity when compared to the effects of single agent treatment. The combination of the two treatment modalities has at least an additive if not a synergistic antitumour effect. Low (i) First of all the efficacy may be due to the reduction of day 3 tumour load by CY prior to the administration of IL-2. This reduction may be to such a low level of tumour load that treatment with low dose IL-2 will have a further significant tumour reducing effect. It is well known that many biologicals, when used alone, exert significant antitumour effects only when the tumour load is small (Bast & Bast, 1976; Eggermont et al., 1986a) . It is important to realize that the dose of CY, as used in our experiments, has no negative effect on in vivo activation of NK cells (Li et al., 1987) .
(ii) The effect of the administration of CY on day 3 may be due to its damage to tumour cells to such a degree that they become more susceptible to lysis by LAK cells, as has been suggested by Papa and coworkers (1988) . Conversely immunotherapy may render tumour cells more susceptible to subsequent chemotherapy (Ades et al., 1987) , which might explain the efficacy of the administration of a second dose of CY on day 8 in our experiments.
(iii) The significant impact of a second dose of CY on day 8 may well reflect a different mechanism that can potentiate the effects of immunotherapy. Several authors have suggested that a most important mechanism by which CY can enhance immunotherapeutic regimens is by removal of suppressor cells (Polak & Turk, 1974; North, 1982; Greenberg et al., 1985) . It has been shown very elegantly by North (1984) that suppressor cells play an increasingly important role seven or more days after tumour inoculation, and that their removal facilitates adoptive immunotherapy.
(iv) Alternatively one may hypothesize that the abrogation of the primary immune response by cyclophosphamide (Anderson et al., 1986; Eggermont et al., 1986b) vivo in the outcome of treatment with IL-2 and LAK cells (Eggermont et al., 1987b). (v) Finally the hepatotoxic and nephrotoxic effects of IL-2 (Matory et al., 1985) may have altered considerably the pharmacokinetics and metabolism of CY (given on day 8) and may thus have influenced its half life and enhanced its tumour kill.
In conclusion, we have shown that the efficacy of adoptive immunotherapy with low to moderate doses of conjunction with the adoptive transfer of LAK cells can be greatly enhanced by the administration of low doses of cyclophosphamide. This is of importance since the toxicity associated with high doses of IL-2 is quite severe and a major obstacle in obtaining cures with immunotherapeutic regimens alone (Matory et al., 1985; Lotze et al., 1986) . In view of the efficacy of a second dose of CY we are currently concentrating our efforts on the development of more effective treatment schedules with repetitive treatment cycles.
